Category - Developments

Developments

Lucid reports positive data from ESOGUARD BE-1 study in BE and EAC patients

Lucid Diagnostics (NASDAQ:LUCD) announced positive results from its clinical validation study of EsoGuard Esophageal DNA test on samples collected from patients with Barrett’s Esophagus (BE) and esophageal...

July 5, 2024

Developments

CureVac unveils restructuring plan to intensify focus on mRNA projects

CureVac (NASDAQ:CVAC) has announced a restructuring plan aimed at increasing its focus on high-value messenger RNA (mRNA) initiatives, with a particular emphasis on oncology and unmet medical needs. The company will...

July 5, 2024

Developments

PharmaJet’s innovative needle-free system chosen for WHO polio immunization campaign in Somalia

Closely-held PharmaJet announced that its Tropis Intradermal (ID) Needle-free System was selected by WHO for use in a house-to-house immunization campaign targeting more than 170,000 children, age four to 59 months, in...

June 27, 2024

Developments

Lyell announces promising clinical data in TNBC

Lyell Immunopharma (Nasdaq:LYELL) has reported initial clinical and translational data from its Phase 1 trial of LYL797, a first-generation reprogrammed ROR1 CAR T cell product candidate enhanced with proprietary anti...

June 26, 2024

Developments

ANEW reports European patent for novel gene sequence and delivery systems in neurodegenerative disease

ANEW Medical (NASDAQ:WENA) has been granted and issued a patent from the European Patent Office (EPO) for the patent application covering the company’s secreted Klotho gene sequence and gene delivery system, intended...

June 26, 2024

Developments

Entrada reports positive data from Phase 1 DMD trial

Entrada Therapeutics (NASDAQ:TRDA) has announced positive preliminary data from its Phase 1 clinical trial evaluating the safety and tolerability of a single dose of ENTR-601-44-101 in patients with Duchenne Muscular...

June 24, 2024

Developments

SOPHiA GENETICS expands oncology portfolio with new RAM application

SOPHiA GENETICS (NASDAQ:SOPH) has announced its new residual acute myeloid (RAM) application, SOPHiA DDM RAM Solution, supporting measurable residual disease (MRD) testing to help monitor cancer and outpace relapse. The...

June 24, 2024

Developments

BioRestorative Therapies gains media attention for key regenerative medicine programs

Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and...

June 20, 2024

Developments

OneMedNet forges alliance with clinical trial design and software global leader

OneMedNet (NASDAQ:ONMD) announced that it has entered into a significant iRWD customer data licensing agreement, partnering with an undisclosed U.S.-based global leader in clinical trial design and software with...

June 14, 2024

Developments

Former Hepion CEO sues over departure; cites bad faith dealings with investor

Former Hepion Pharmaceuticals (NASDAQ:HEPA) CEO, Robert Foster, PharmD, PhD, is suing the company and its Board members for illegal termination of his employment, breach of contract, and breach of the covenant of good...

June 13, 2024

Category - Developments

Lucid reports positive data from ESOGUARD BE-1 study in BE and EAC patients

CureVac unveils restructuring plan to intensify focus on mRNA projects

PharmaJet’s innovative needle-free system chosen for WHO polio immunization campaign in Somalia

Lyell announces promising clinical data in TNBC

ANEW reports European patent for novel gene sequence and delivery systems in neurodegenerative disease

Entrada reports positive data from Phase 1 DMD trial

SOPHiA GENETICS expands oncology portfolio with new RAM application

BioRestorative Therapies gains media attention for key regenerative medicine programs

OneMedNet forges alliance with clinical trial design and software global leader

Former Hepion CEO sues over departure; cites bad faith dealings with investor

General

More